Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Desai K, McManus JM, Sharifi N (2021) Hormonal therapy for prostate cancer. Endocr Rev 42:354–373
2. Gómez Rivas J, Fernandez L, Abad-Lopez P, Moreno-Sierra J (2023) Androgen deprivation therapy in localized prostate cancer. Current status and future trends. ActasUrol Esp 47:398–407
3. Nguyen PL, Alibhai SMH, Smith MR et al (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67:825–836
4. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410–6417
5. Wang A, Obertová Z, Brown C, Lawrenson R et al (2015) Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. BMC Cancer 15:837